Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Summary
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.
Visit the original source for the full article